51茶馆

Table 1: unaudited sales reports: measured sales

Aggregate net sales subject to the affordability mechanism (measured sales):

Year	2019 voluntary scheme	Statutory scheme	Parallel imports	Total
2018	拢 8,855m	拢1,654尘	拢736尘	拢11,246尘
2019 Q1	拢 2,196m	拢 411m	拢183尘	拢 2,789m
2019 Q2	拢 2,179m	拢 422m	拢170尘	拢 2,771m
2019 Q3	拢 2,304m	拢 419m	拢165尘	拢 2,889m
2019 Q4	拢 2,402m	拢 423m	拢179尘	拢 3,004m
2019	拢 9,083m	拢1,671尘	拢697尘	拢11,451尘
2020 Q1	拢 2,748m	拢 99m	拢191尘	拢 3,038m
2020 Q2	拢 2,407m	拢 95m	拢176尘	拢 2,678m
2020 Q3	拢 2,621m	拢 87m	拢198尘	拢 2,906m
2020 Q4	拢 2,953m	拢 98m	拢200尘	拢 3,251m
2020	拢10,728尘	拢 379m	拢766尘	拢11,873尘

Table 1 notes

1. Table 1 sets out aggregate information about measured sales subject to the affordability mechanism. It includes information received on parallel imports and information from audited annual sales reports and unaudited quarterly sales reports provided by members of the 2019 voluntary scheme and the statutory scheme.

2. The baseline for measured sales in respect of the statutory scheme and parallel imports has been calculated in accordance with annex 4, paragraph 1 of the 2019 voluntary scheme.

3. Measured sales is defined in the glossary of the 2019 voluntary scheme for branded medicines pricing and access as 鈥渟ales of scheme products by scheme members, statutory scheme sales and parallel import sales, but excluding exemptions from measured sales鈥�.

4. Figures for the 2019 voluntary scheme reflect any audited sales reports received. Annual totals from 2019 onwards for the statutory scheme reflect any audited sales reports received.

Measured sales in any particular period reflects all relevant scheme members in either the 2019 voluntary scheme or statutory scheme during that period. For example, several companies moved from the statutory scheme to the voluntary scheme at the start of 2020. Those companies鈥� measured sales will appear under the statutory scheme in 2019 but the voluntary scheme in 2020.

Table 2: 2019 voluntary scheme sales reports: eligible sales and resulting total scheme payments

Period	Aggregate eligible sales (column 1)	Resulting aggregate scheme payments (column 2)
2019 Q1	拢 2,072m	拢199尘
2019 Q2	拢 2,118m	拢203尘
2019 Q3	拢 2,258m	拢217尘
2019 Q4	拢 2,342m	拢225尘
2019	拢 8,792m	拢844尘
2020 Q1	拢 2,543m	拢150尘
2020 Q2	拢 2,287m	拢135尘
2020 Q3	拢 2,496m	拢147尘
2020 Q4	拢 2,743m	拢162尘
2020	拢10,069尘	拢594尘

Table 2 notes

1. Table 2, which is derived from unaudited quarterly sales reports and any audited annual sales reports received from members of the 2019 voluntary scheme, sets out aggregate information showing eligible sales covered by the scheme payment and the resulting scheme payments.

There are 2 columns of information:

• column 1 鈥� aggregate eigible sales
• column 2 鈥� resulting aggregate scheme payments due for the respective periods

Note: eligible sales is defined in the glossary of the 2019 voluntary scheme as 鈥渟ales of scheme products but excluding exemptions from eligible sales鈥�. The percentage payment applies to these sales. Eligible sales excludes certain types of sales, including the first 拢5 million of sales by a medium-sized company and new active substance (NAS) sales. Both of these sales categories are, however, included in measured sales and, therefore, the calculation of the overall sum to be repaid across all scheme members.

Table 3: statutory scheme sales reports: net sales covered by the statutory scheme payment and resulting payments

Statutory scheme payment and resulting payments	Jan to Mar 2019	Apr to Jun 2019	Jul to Sep 2019	Oct to Dec 2019	2019
Aggregate net sales covered by the applicable annual statutory scheme payment (a)	拢140尘	拢137尘	拢173尘	拢191尘	拢633尘
Resulting aggregate statutory scheme payment (b)	拢 14m	拢 14m	拢 17m	拢 19m	拢63尘
Net sales of extant frameworks and public contracts subject to 7.8% payment (c)	拢 53m	拢 85m	拢 81m	拢 76m	拢308尘
Resulting statutory scheme 7.8% payment (d)	拢 4m	拢 7m	拢 6m	拢 6m	拢24尘
Total resulting statutory scheme payment (b + d)	拢 18m	拢 20m	拢 24m	拢 25m	拢 87m

Statutory scheme payment and resulting payments	Jan to Mar 2020	Apr to Jun 2020	Jul to Sep 2020	Oct to Dec 2020	2020
Aggregate net sales covered by the applicable annual statutory scheme payment (a)	拢5尘	拢7尘	拢10尘	拢11尘	拢33尘
Resulting aggregate statutory scheme payment (b)	拢1尘	<拢1尘	<拢1尘	拢 1m	拢 2m
Net sales of extant frameworks and public contracts subject to 7.8% payment (c)	拢4尘	拢4尘	拢4尘	拢 5m	拢17尘
Resulting statutory scheme 7.8% payment (d)	<拢1尘	<拢1尘	<拢1尘	<拢1尘	拢 1m
Total resulting statutory scheme payment (b + d)	拢1尘	拢1尘	拢1尘	拢1尘	拢3尘

Table 3 notes

Table 3 is derived from audited and unaudited statutory scheme sales reports. It sets out aggregate unaudited quarterly information showing net sales covered by the statutory scheme payment and the resulting payments.

General notes

Note 1: The information in all tables is that held on the Department of Health and Social Care鈥檚 database at 10 February 2021.

Note 2: Totals may not sum due to rounding.

Note 3: All tables are subject to future correction such as where audited data replaces best available data and will be updated at each quarterly publication point to reflect the latest available information. The audit and reconciliation arrangements are set out in paragraphs 4.26 to 4.31 of the 2019 voluntary scheme. The statutory scheme audit requirements are set out at paragraph 23 of the regulations.